Total Q3 revenue of $37.7 million, including $33.4 million in U.S. net product revenue for neffy® neffy U.S. market share reached 5% overall and 9% in field-targeted accounts, supporting the company’s updated targeted
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a commercial biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their Options
If you purchased or acquired
New York, New York--(Newsfile Corp. - October 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) between March 9, 2026 and June
New York, New York--(Newsfile Corp. - October 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) between March 9, 2026 and June
NEW YORK, Oct. 2, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) between March 9, 2026 and June 24, 2026, inclusive
NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) between March 9, 2026 and June 24,
If you purchased or acquired ARS securities between March 9, 2026, and June 24, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email
New York, New York--(Newsfile Corp. - October 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company")
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ARS Pharmaceuticals To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired
New York, New York--(Newsfile Corp. - September 30, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) between March 9, 2026 and
Wall Street called the missed CVS Caremark formulary date a "negative shock" — a securities class action alleges ARS Pharmaceuticals built analyst expectations on a July 1, 2026 coverage timeline that was never
New York, New York--(Newsfile Corp. - September 29, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company")
NEW YORK, Sept. 29, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors that Eric Karas, Chief Commercial Officer of ARS Pharmaceuticals Inc. (NASDAQ:SPRY), is named as an individual defendant in a securities class
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ARS Pharmaceuticals, Inc., ("ARS" or the "Company") (NASDAQ:SPRY) investors of a class action on behalf of investors that
